Cargando…

A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature

OBJECTIVE: We describe a family with a novel mutation in the TNF Receptor Superfamily Member 1A (TNFRSF1A) gene causing TNF receptor–associated periodic syndrome (TRAPS) with renal AA amyloidosis. METHODS: Case series of affected family members. We further investigated the plasma metabolome of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Steiner, Joachim D, Annibal, Andrea, Laboy, Raymond, Braumann, Marie, Göbel, Heike, Laasch, Valentin, Müller, Roman-Ulrich, Späth, Martin R, Antebi, Adam, Kubacki, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547530/
https://www.ncbi.nlm.nih.gov/pubmed/36752501
http://dx.doi.org/10.1093/rheumatology/kead068
_version_ 1785115075010363392
author Steiner, Joachim D
Annibal, Andrea
Laboy, Raymond
Braumann, Marie
Göbel, Heike
Laasch, Valentin
Müller, Roman-Ulrich
Späth, Martin R
Antebi, Adam
Kubacki, Torsten
author_facet Steiner, Joachim D
Annibal, Andrea
Laboy, Raymond
Braumann, Marie
Göbel, Heike
Laasch, Valentin
Müller, Roman-Ulrich
Späth, Martin R
Antebi, Adam
Kubacki, Torsten
author_sort Steiner, Joachim D
collection PubMed
description OBJECTIVE: We describe a family with a novel mutation in the TNF Receptor Superfamily Member 1A (TNFRSF1A) gene causing TNF receptor–associated periodic syndrome (TRAPS) with renal AA amyloidosis. METHODS: Case series of affected family members. We further investigated the plasma metabolome of these patients in comparison with healthy controls using mass spectrometry. RESULTS: In all symptomatic family members, we detected the previously undescribed variant c.332A>G (p.Q111R) in the TNFRSF1A gene. Canakinumab proved an effective treatment option leading to remission in all treated patients. One patient with suspected renal amyloidosis showed near normalization of proteinuria under treatment. Analysis of the metabolome revealed 31 metabolic compounds to be upregulated and 35 compounds to be downregulated compared with healthy controls. The most dysregulated metabolites belonged to pathways identified as arginine biosynthesis, phenylalanine, tyrosine and tryptophan biosynthesis, and cysteine and methionine metabolism. Interestingly, the metabolic changes observed in all three TRAPS patients seemed independent of treatment with canakinumab and subsequent remission. CONCLUSION: We present a novel mutation in the TNFRSF1A gene associated with amyloidosis. Canakinumab is an effective treatment for individuals with this new likely pathogenic variant. Alterations in the metabolome were most prominent in the pathways related to arginine biosynthesis, tryptophan metabolism, and metabolism of cysteine and methionine, and seemed to be unaffected by treatment with canakinumab. Further investigation is needed to determine the role of these metabolomic changes in the pathophysiology of TRAPS.
format Online
Article
Text
id pubmed-10547530
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105475302023-10-04 A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature Steiner, Joachim D Annibal, Andrea Laboy, Raymond Braumann, Marie Göbel, Heike Laasch, Valentin Müller, Roman-Ulrich Späth, Martin R Antebi, Adam Kubacki, Torsten Rheumatology (Oxford) Basic Science OBJECTIVE: We describe a family with a novel mutation in the TNF Receptor Superfamily Member 1A (TNFRSF1A) gene causing TNF receptor–associated periodic syndrome (TRAPS) with renal AA amyloidosis. METHODS: Case series of affected family members. We further investigated the plasma metabolome of these patients in comparison with healthy controls using mass spectrometry. RESULTS: In all symptomatic family members, we detected the previously undescribed variant c.332A>G (p.Q111R) in the TNFRSF1A gene. Canakinumab proved an effective treatment option leading to remission in all treated patients. One patient with suspected renal amyloidosis showed near normalization of proteinuria under treatment. Analysis of the metabolome revealed 31 metabolic compounds to be upregulated and 35 compounds to be downregulated compared with healthy controls. The most dysregulated metabolites belonged to pathways identified as arginine biosynthesis, phenylalanine, tyrosine and tryptophan biosynthesis, and cysteine and methionine metabolism. Interestingly, the metabolic changes observed in all three TRAPS patients seemed independent of treatment with canakinumab and subsequent remission. CONCLUSION: We present a novel mutation in the TNFRSF1A gene associated with amyloidosis. Canakinumab is an effective treatment for individuals with this new likely pathogenic variant. Alterations in the metabolome were most prominent in the pathways related to arginine biosynthesis, tryptophan metabolism, and metabolism of cysteine and methionine, and seemed to be unaffected by treatment with canakinumab. Further investigation is needed to determine the role of these metabolomic changes in the pathophysiology of TRAPS. Oxford University Press 2023-02-08 /pmc/articles/PMC10547530/ /pubmed/36752501 http://dx.doi.org/10.1093/rheumatology/kead068 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Basic Science
Steiner, Joachim D
Annibal, Andrea
Laboy, Raymond
Braumann, Marie
Göbel, Heike
Laasch, Valentin
Müller, Roman-Ulrich
Späth, Martin R
Antebi, Adam
Kubacki, Torsten
A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature
title A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature
title_full A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature
title_fullStr A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature
title_full_unstemmed A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature
title_short A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature
title_sort novel tnfrsf1a mutation associated with tnf-receptor-associated periodic syndrome and its metabolic signature
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547530/
https://www.ncbi.nlm.nih.gov/pubmed/36752501
http://dx.doi.org/10.1093/rheumatology/kead068
work_keys_str_mv AT steinerjoachimd anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT annibalandrea anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT laboyraymond anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT braumannmarie anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT gobelheike anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT laaschvalentin anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT mullerromanulrich anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT spathmartinr anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT antebiadam anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT kubackitorsten anoveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT steinerjoachimd noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT annibalandrea noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT laboyraymond noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT braumannmarie noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT gobelheike noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT laaschvalentin noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT mullerromanulrich noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT spathmartinr noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT antebiadam noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature
AT kubackitorsten noveltnfrsf1amutationassociatedwithtnfreceptorassociatedperiodicsyndromeanditsmetabolicsignature